Trial reportHypertension (Dallas, Tex. : 1979)2013
Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
Trial report in Hypertension (Dallas, Tex. : 1979), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000542. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Pharmacological interventions for heart failure in people with chronic kidney disease.The Cochrane database of systematic reviews · 2020Pooled it
- Mortality and Morbidity Among Individuals With Hypertension Receiving a Diuretic, ACE Inhibitor, or Calcium Channel Blocker: A Secondary Analysis of a Randomized Clinical Trial.JAMA network open · 2023Trial
- Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial.Hypertension (Dallas, Tex. : 1979) · 2016Trial
- Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.Journal of the American Society of Hypertension : JASH · 2014Trial
- Article
- Geroscience-guided repurposing of FDA-approved drugs to target aging: A proposed process and prioritization.Aging cell · 2022Review
- Sex differences in hypertension. Do we need a sex-specific guideline?Frontiers in cardiovascular medicine · 2022Review
- Quantifying representativeness in randomized clinical trials using machine learning fairness metrics.JAMIA open · 2021Article
- Effects of Posttrial Antihypertensive Drugs on Morbidity and Mortality: Findings from 15-Year Passive Follow-Up after ALLHAT Ended.International journal of hypertension · 2021Article
- Sex differences in stroke co-morbidities.Experimental neurology · 2020Review
- Gender Differences in Cardiovascular Pharmacotherapy-the Example of Hypertension: A Mini Review.Frontiers in pharmacology · 2020Review
- Hypertension in Premenopausal and Postmenopausal Women.Current hypertension reports · 2019Review
- Sex Differences in Hypertension: Where We Have Been and Where We Are Going.American journal of hypertension · 2018Review
- Comparative effectiveness of antihypertensive drugs in nondiabetic patients with hypertension: A population-based study.Journal of clinical hypertension (Greenwich, Conn.) · 2017Article
- Gender Differences in Antihypertensive Treatment: Myths or Legends?High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2016Review
- Primary and secondary prevention of ischemic heart disease in women.Current atherosclerosis reports · 2015Review
- Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE Study.Journal of the American Heart Association · 2014Observational
- Which thiazide to choose as add-on therapy for hypertension?Integrated blood pressure control · 2014Review
- Hypertension in women.Kidney international supplements · 2013Article
- Hypertension: Do calcium-channel blockers increase breast cancer risk?Nature reviews. Cardiology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
To determine whether an angiotensin-converting enzyme inhibitor (lisinopril) or calcium channel blocker (amlodipine) is superior to a diuretic (chlorthalidone) in reducing cardiovascular disease incidence in sex subgroups, we carried out a prespecified subgroup analysis of 15 638 women and 17 719 men in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Total follow-up (active treatment + passive surveillance using national administrative databases to ascertain deaths and hospitalizations) was 8 to 13 years. The primary outcome was fatal coronary heart disease or nonfatal myocardial infarction. Secondary outcomes included all-cause mortality, stroke, combined cardiovascular disease (coronary heart disease death, nonfatal myocardial infarction, stroke, angina, coronary revascularization, heart failure [HF], or peripheral vascular disease), and end-stage renal disease. In-trial rates of HF, stroke, and combined cardiovascular disease were significantly higher for lisinopril compared with chlorthalidone, and rates of HF were significantly higher for amlodipine compared with chlorthalidone in both men and women. There were no significant treatment sex interactions. These findings did not persist through the extension period with the exception of the HF result for amlodipine versus chlorthalidone, which did not differ significantly by sex. For both women and men, rates were not lower in the amlodipine or lisinopril groups than in the chlorthalidone group for either the primary coronary heart disease outcome or any other cardiovascular disease outcome, and chlorthalidone-based treatment resulted in the lowest risk of HF. Neither lisinopril nor amlodipine is superior to chlorthalidone for initial treatment of hypertension in either women or men. Clinical Trial Registration- clinicaltrials.gov; Identifier: NCT00000542.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.